AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02008084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Trial: NCT00102128
Drug: Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00924534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00924534
Drug: SLV337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV337 400 mg/day
Trial: NCT00924534
Drug: SLV337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV337 800 mg/day
Trial: NCT00924534
Drug: SLV337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV337 1400 mg/day
Trial: NCT02412228
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily
Trial: NCT00044213
Drug: EDTA Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 40 infusions of EDTA placebo.
Trial: NCT03008915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken once per day in the morning
Trial: NCT00118404
Drug: Continuation phase fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of fluoxetine was increased to 40 mg over 8 months.
Trial: NCT01585558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00287716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Trial: NCT02085018
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT00755118
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Trial: NCT02766868
Drug: FACE-Flu/Bu/Cy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
Trial: NCT00393211
Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00393211
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01705249
Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
Trial: NCT01922271
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
Trial: NCT01922271
Drug: Placebo to NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
Trial: NCT00457691
Drug: 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
Trial: NCT00457691
Drug: levo- leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg/m2 iv; day 1 every 14 days
Trial: NCT00457691
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
Trial: NCT01720563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
Trial: NCT00346125
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
Trial: NCT00346125
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
Trial: NCT01101685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days dosing at 10mg daily
Trial: NCT06188611
Drug: Huazhi Rougan Granule Placebo granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
Trial: NCT04633980
Drug: Mixture 3,6% H2 in N2 (96.4%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
Trial: NCT02758912
Drug: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00328393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01559480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule takes 1 capsule before bedtime for 6 months
Trial: NCT00453323
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
Trial: NCT02996500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00391547
Drug: Frio Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03828162
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00698802
Drug: EX1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target titration scheme, s.c. injection
Trial: NCT01100320
Drug: Reformulated OXY (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 40-mg tablet x 1 dose taken with food
Trial: NCT01100320
Drug: Original OxyContin® (OXY) (oxycodone HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
Trial: NCT00003519
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02728089
Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Trial: NCT00782717
Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
Trial: NCT00782717
Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED)
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
Trial: NCT01596751
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
Trial: NCT02446717
Drug: ABT-493, ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-493 (tablet) dosed with ABT-530 (tablet)
Trial: NCT02446717
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT01191086
Drug: USL255
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00541749
Drug: rhuMAb IFNalpha
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00893373
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AML chemotherapy plus placebo
Trial: NCT01420718
Drug: iRoot BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
Trial: NCT00550407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily
Trial: NCT00774293
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
Trial: NCT00774293
Drug: Arnica and Bryonia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
Trial: NCT01236521
Drug: Pharmacological (MED)
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment.
Trial: NCT00398658
Drug: gentamycin and clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04203836
Drug: LEO 152020 Tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: film-coated tablet
Trial: NCT01908452
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg/d during 12 weeks
Trial: NCT03946748
Drug: REGN3918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
Trial: NCT02515734
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02515734
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03216408
Drug: Neuronox
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00596167
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
Trial: NCT03829917
Drug: Miltefosine and Paromomycin
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 days of miltefosine plus 28 days of Paromomycin cream
Trial: NCT03829917
Drug: paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 days of paromomycin creaam
Trial: NCT01367548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05399394
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
Trial: NCT01738802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will take a placebo.
Trial: NCT00478335
Drug: hydrochlorothiazide/amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
Trial: NCT00478335
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg QD or 50 mg BID x 8 days depending on subject weight
Trial: NCT00478335
Drug: placebo for calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one nasal spray daily
Trial: NCT03009006
Drug: Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
Trial: NCT03009006
Drug: Calcium Hydroxide Paste - Non-Setting
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
Trial: NCT00444613
Drug: E0302 (mecobalamin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
Trial: NCT00444613
Drug: E0302 (mecobalamin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
Trial: NCT00444613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection, placebo twice a week for 3.5 years.
Trial: NCT03971409
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00937846
Drug: GSK1034702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 5 mg dose in liquid formulation
Trial: NCT00540202
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken twice daily for 3 days according to weight based guidelines.
Trial: NCT01028040
Drug: AZD3043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, single dose
Trial: NCT01028040
Drug: AZD3043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, single dose
Trial: NCT02925195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205762
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stratum I
Trial: NCT02205762
Drug: INDOMETHACIN
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
Trial: NCT02205762
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fixed dose weekly orally for total treatment duration of 24 months.
Trial: NCT02178540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose (4 capsules) of placebo
Trial: NCT02783196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
Trial: NCT03178994
Drug: Hydrophilic Cream
RxNorm normalized name: HYDROPHILIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic cream (in-house preparation) applies twice daily
Trial: NCT00199589
Drug: Botulinic toxin (Botox)
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
Trial: NCT01546090
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules were filled with starch
Trial: NCT00365638
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00982033
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo qd for 24 weeks
Trial: NCT01830010
Drug: Study Part 1: KRP203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive KRP203 for 111 days
Trial: NCT00751803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01830010
Drug: Study Part 2: KRP203 lower dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01830010
Drug: Study Part 2: KRP203 higher dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00117572
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
Trial: NCT01555736
Drug: grass (80%) and rye (20%) pollens allergoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
Trial: NCT03650036
Drug: Pulp Therapy CTZ Paste
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
Trial: NCT00702806
Drug: Puregon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Puregon® 150 IU
Trial: NCT00702806
Drug: Orgalutran®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Orgalutran® 0.25 mg
Trial: NCT00702806
Drug: Pregnyl®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Pregnyl® 10,000 IU
Trial: NCT03650036
Drug: Pulp Therapy ZOE Paste
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
Trial: NCT00878306
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 62.5 mg daily x3 days, then 250 mg daily x3 days
Trial: NCT00878306
Drug: Disulfiram + Efavirenz
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Trial: NCT04627155
Drug: LY03003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine,extended-release microspheres
Trial: NCT01726530
Drug: transdermal fentanyl patch (50 mcg/hour)
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01726530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00878306
Drug: Disulfiram + Atazanavir
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Trial: NCT00878306
Drug: Disulfiram + Ritonavir
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Trial: NCT02187900
Drug: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
Trial: NCT01219699
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Trial: NCT00476827
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
Trial: NCT02163824
Drug: KPI-121 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.